KOSDAQBiotech & Pharma397030

AprilBio

₩16,910▼ 20.61%2026-10-02 close

Market Cap

₩469.1B

Turnover

₩29B

Volume

1.6M

Shares out.

27.6M

PER

—

PBR

4.2×

EPS

-₩394

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Cash-Rich Now, but APB-A1 Uncertainty Lingers

April Bio has secured KRW 346.8 billion in fresh capital from TKG and IMM, but the discontinuation of the thyroid eye disease indication for its key candidate APB-A1 has put market confidence in its SAFA platform back to the test.

1
In July 2026, a KRW 346.8bn third-party share placement by a TKG Hugem-IMM consortium was completed, simultaneously changing both the registered largest shareholder (an IMM-affiliated SPC) and de facto control (TKG Hugem).
2
In August 2026, partner Lundbeck decided not to continue APB-A1 development in the thyroid eye disease (TED) indication, triggering a sharp after-hours share price decline.
3
The other pipeline asset, APB-R3 for atopic dermatitis, reported a topline 33% EASI improvement at week 12 after two doses, with partner Evommune set to disclose secondary endpoint and biomarker full data on September 30, 2026.
4
2025 revenue of KRW 2.17bn and an operating loss of KRW 7.26bn marked a swing from 2024's KRW 27.5bn revenue and KRW 16.9bn operating profit, reflecting how milestone-driven licensing revenue causes large swings.
5
Rather than pivoting to in-house development, the company is maintaining its licensing-out strategy while expanding into RNA modalities (AOC, siRNA) through an equity stake in Curigin.

Business structure

Founded in 2013 and listed on KOSDAQ in 2022 under the technology special listing track, April Bio operates a licensing-out business model, out-licensing drug candidates at preclinical or early clinical stages.

Its core proprietary platform is SAFA, which uses a serum-albumin-binding Fab fragment to extend a drug's half-life in the body, complemented by REMAP, a next-generation multi-target platform expandable to up to four targets.

Its two flagship candidates are APB-A1, a CD40L inhibitor out-licensed to Denmark's Lundbeck in 2021, and APB-R3, an IL-18 binding protein (IL-18BP) fusion protein out-licensed to US-based Evommune in 2024.

The company has completed a cumulative five out-licensing deals since founding, with reported cumulative deal value ranging from roughly KRW 900bn to KRW 1.2 trillion depending on the source.

In June 2026 it signed a change-of-control agreement and a combined KRW 346.8bn third-party share placement with a consortium of TKG Group affiliate TKG Hugem and the IMM Investment Group, with payment completed in July 2026; registered largest-shareholder status shifted to an IMM-affiliated special purpose company while de facto control, via a board majority, moved to TKG Hugem.

The company stated it plans to deploy the proceeds into expanded R&D, in-licensing, strategic equity investments, and M&A to broaden its pipeline.

It has also acquired a 25.26% stake in domestic RNA therapeutics firm Curigin, becoming its second-largest shareholder and adding antibody-oligonucleotide conjugate (AOC) and siRNA modalities to its toolkit.

In terms of competitive positioning, domestic peers with similar half-life-extending antibody platforms include Hanall Biopharma, while on an indication basis its candidates are benchmarked against global blockbuster atopic dermatitis therapies such as Sanofi's Dupixent and Eli Lilly's Ebglyss.

Earnings trend

Quarterly revenue · Operating profit

₩0-₩2.7B25Q2₩0-₩2.5B25Q3₩0-₩2B25Q4₩700M-₩2.2B26Q1₩0-₩2.9B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩200M-₩11.5B2022₩0-₩13.4B2023₩27.5B₩16.9B2024₩2.2B-₩7.3B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩0	-₩2.7B	—
2025Q3	₩0	-₩2.5B	—
2025Q4	₩0	-₩2B	—
2026Q1	₩700M	-₩2.2B	−302.3%
2026Q2	₩0	-₩2.9B	—

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩200M	-₩11.5B	-₩9B	−5737.2%	−13.0%	2.8%
2023	₩0	-₩13.4B	-₩14.1B	—	−24.5%	38.0%
2024	₩27.5B	₩16.9B	₩20B	61.3%	22.0%	9.5%
2025	₩2.2B	-₩7.3B	-₩9.7B	−334.4%	−10.1%	0.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04

Earnings analysis

Annual results are highly volatile, driven by the timing of licensing milestone recognition rather than recurring sales.

In 2024, the company posted revenue of KRW 27.5bn, operating profit of KRW 16.9bn, and net income (owners) of KRW 20.0bn, but in 2025 revenue collapsed to KRW 2.17bn, swinging to an operating loss of KRW 7.26bn and a net loss of KRW 9.73bn. 2023 (zero revenue, operating loss of KRW 13.4bn, net loss of KRW 14.1bn) and 2022 (revenue of KRW 0.2bn, operating loss of KRW 11.5bn, net loss of KRW 9.0bn) were similarly periods with no meaningful revenue recognition against substantial R&D spending.

On a quarterly basis, revenue was zero throughout 2025Q2 to 2025Q4, while operating losses gradually narrowed from KRW 2.66bn to KRW 2.50bn to KRW 2.00bn, and net losses moved from KRW 3.09bn to KRW 4.96bn (widening in Q3) to KRW 2.27bn.

In 2026Q1, revenue of KRW 0.73bn was recognized and the operating loss widened slightly to KRW 2.19bn, yet net income turned positive at KRW 0.20bn, likely reflecting non-operating items.

However, 2026Q2 reverted to zero revenue with an operating loss of KRW 2.92bn and a net loss of KRW 1.99bn, reaffirming the loss-making trend.

Over the trailing four quarters (2025Q3 to 2026Q2), cumulative net loss attributable to owners was roughly KRW 9.01bn, underscoring that the company remains pre-cash-flow-positive from operations.

This pattern reflects a business model dependent on upfront and milestone payments rather than steady sales, with future results hinging on partner clinical progress and the timing of new licensing agreements.

Industry analysis

April Bio operates in the autoimmune and inflammatory disease market, an area where global pharma majors are focused on extending half-life, reducing dosing frequency, and identifying novel mechanisms.

The atopic dermatitis market in particular has been projected by IBK Securities to grow to roughly KRW 40 trillion by 2030, a space already led by blockbuster therapies such as Sanofi's Dupixent and Eli Lilly's Ebglyss.

No IL-18-targeting therapy has been commercialized to date, meaning APB-R3 could position itself as a first-in-class candidate if efficacy is confirmed.

Conversely, CD40L-targeting therapies are a competitive mechanism already being pursued by multiple large pharma companies in neuroimmunology indications such as multiple sclerosis and lupus, and competition for a new indication for APB-A1 may intensify now that the TED pathway has been abandoned.

Domestically, Hanall Biopharma is often cited as a comparable company with a similar half-life-extending antibody platform, while platform-driven licensing peers such as LegoChem Biosciences, ABL Bio, and Olix are used in similar investment frameworks.

Broadly, early-stage out-licensing to major pharma has become a key funding and validation pathway for Korean biotechs, and small-cap KOSDAQ biotech names tend to exhibit sharp share-price volatility around clinical data readouts.

Outlook

The nearest confirmable milestone is the full secondary-endpoint and biomarker data for the EVO301 (APB-R3) Phase 2a trial that partner Evommune plans to disclose on September 30, 2026.

The previously reported topline showed EASI improvements of 23%, 34%, and 33% versus placebo at weeks four, eight, and twelve, respectively, after just two doses.

Evommune has indicated plans to expand into indications such as ulcerative colitis, which would open the door to additional milestone inflows if new trials commence.

By contrast, after Lundbeck decided not to continue development of APB-A1 in the TED indication, the company stated it is reviewing a pivot to other indications where the CD40-CD40L pathway is more directly implicated, such as myasthenia gravis or neuromyelitis optica spectrum disorder.

Management has said a new indication would not require restarting Phase 1 trials and could proceed directly to Phase 2, though specific new indications and timelines have not yet been disclosed.

Following the KRW 346.8bn capital raise, the company said it plans to shift to a parallel R&D structure to accelerate pipeline expansion, while also building out AOC and siRNA pipelines through its Curigin collaboration.

With IMM Investment Group set to support strategy-setting, global business development, licensing, and M&A execution, whether a new REMAP-platform licensing deal materializes remains a key point to watch in the second half and beyond.

Valuation

PER

—

PBR

4.2×

ROE

-9.7%

EPS

-₩394

BPS

₩4,272

Dividend per share

₩0

Because the equity base underlying valuation was substantially enlarged by the large July 2026 share placement, direct comparison with historical trading bands formed prior to the capital raise has clear limitations.

The company's cash holdings have been described as approaching the scale of its market capitalization, meaning the enlarged equity base needs to be factored in when assessing the premium of price to net assets.

The current share price trades below the subscription price paid by the strategic and financial investors who participated in June's placement.

With revenue absent or minimal in many quarters, net-income-based multiples are difficult to compute, and enterprise value remains heavily dependent on clinical data readouts and the success of licensing negotiations. There is no dividend payment history, limiting the appeal from a yield perspective.

Several brokerages issued constructive price targets through the first half of 2026, but it should be noted that these predate public disclosure of the discontinuation of APB-A1's TED indication development.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04

Bull factors

Expanded R&D Firepower from Large Capital Injection

In July 2026, the KRW 346.8bn share placement from the TKG Hugem-IMM consortium was completed, bringing total liquidity including existing cash to roughly KRW 437bn.

The company said it plans to deploy these funds toward a parallel R&D structure, pipeline expansion, and strategic equity investments, in-licensing, and M&A.

IMM Investment Group has committed to act as an operational partner supporting strategy, global business development, licensing, and M&A execution, going beyond a purely financial investment role.

Positive Topline Data for APB-R3 in Atopic Dermatitis

In the EVO301 (APB-R3) Phase 2a topline reported by partner Evommune, just two doses produced a 33% EASI improvement versus placebo at week 12, an early efficacy level comparable to Dupixent's 35-36% improvement achieved with eight doses over 16 weeks.

Given that no IL-18-targeting therapy has been commercialized to date, confirmed efficacy could position the candidate as a first-in-class therapy. The full secondary-endpoint and biomarker data set for release on September 30, 2026 represents a further validation opportunity.

Proven Licensing Track Record and Modality Diversification

Since founding, the company has completed five licensing-out deals, repeatedly demonstrating the commercial viability of its SAFA platform.

It recently acquired a 25.26% stake in domestic RNA therapeutics firm Curigin, becoming its second-largest shareholder and adding antibody-oligonucleotide conjugate (AOC) and siRNA modalities.

This represents an attempt to broaden from an antibody-centric platform to a multi-modality base, which could feed into future REMAP-based licensing negotiations.

Bear factors

Discontinuation of APB-A1 Development in the TED Indication

In August 2026, partner Lundbeck discontinued further development of APB-A1 in the thyroid eye disease (TED) indication after determining, based on additional data analysis, that the mechanism could not support continued development there.

While the company maintains this does not represent a full return or termination of the candidate, some observers view the loss of the originally planned first indication as a negative signal. The new target indication has not yet been disclosed, leaving uncertainty over the future development direction and timeline.

Discontinuous Revenue Recognition and Persistent Losses

2025 revenue of KRW 2.17bn fell sharply from KRW 27.5bn in 2024, and operating profit swung from a KRW 16.9bn gain to a KRW 7.26bn loss. Revenue was zero across 2025Q2 through Q4 and again in 2026Q2, confirming a stark performance gap between periods with and without milestone inflows.

Under this structure, future results will inevitably remain hostage to the pace of partner clinical progress and contract terms.

Dual Governance Structure and Pressure Relative to Placement Price

A dual governance structure has emerged in which registered majority ownership (an IMM-affiliated special purpose company) and de facto control via board majority (TKG Hugem) are separated, with TKG Hugem holding a call option to acquire the IMM side's stake in stages over the next five years, leaving room for further ownership shifts.

In addition, the current share price trades below the subscription price paid by strategic and financial investors in June's placement, suggesting the benefits of the large capital raise have not yet been fully reflected in the share price.

Risk factors

Clinical and Strategic Pivot Risk

As APB-A1 pivots from TED to a new indication, uncertainties around the new indication's market potential, trial design, and regulatory pathway could recur. For APB-R3, subgroup analyses in the full September data set could also diverge from the topline results.

Partner Dependency Risk

Decision-making authority over development and indication selection for core pipeline assets rests with overseas partners such as Lundbeck and Evommune, meaning pipeline direction depends on strategic judgments outside April Bio's direct control. The timing and scale of milestone receipts are likewise contingent on partners' clinical progress.

Governance and Supply-Demand Risk

Given the call/put option structure between TKG Hugem and the IMM side, share ownership shifts are scheduled to occur over the coming years, warranting ongoing monitoring of long-term supply and demand.

As is typical for small-cap KOSDAQ biotechs, share prices can be highly volatile around clinical data events and sensitive to macro shifts in interest rates and currency.

What to watch next

September 30, 2026
Partner Evommune is scheduled to disclose full secondary-endpoint and biomarker data for the EVO301 (APB-R3) Phase 2a trial. Consistency between the detailed metrics and the earlier topline could be a turning point for how the SAFA platform is assessed.
During Q4 2026
Watch for whether Lundbeck discloses concrete plans on selecting a new indication for APB-A1 (potentially conditions where the CD40-CD40L pathway is more directly implicated, such as myasthenia gravis or NMOSD).
Mid-November 2026
Around the expected filing date for the 2026 Q3 report, it will be worth checking whether revenue is recognized, the pace of operating losses and cash burn, and how proceeds from the large capital raise are being deployed.
During H2 2026
It is worth monitoring whether a new REMAP-platform licensing deal, or concrete progress from the AOC/siRNA joint development with Curigin, is formally announced.

Overall view

April Bio significantly strengthened its financial position in the first half of 2026 by securing KRW 346.8bn from the TKG Hugem-IMM consortium, but this coincided with a negative development in August 2026: the discontinuation of core pipeline candidate APB-A1's development in the TED indication.

The other pipeline asset, APB-R3, showed early efficacy in Phase 2a atopic dermatitis trials comparable to Dupixent on a topline basis, with the full data release scheduled for September 30, 2026 serving as the next checkpoint.

Annual and quarterly results swing sharply based on the timing of licensing milestone recognition, moving from profitability in 2024 back to losses in 2025, with pronounced quarterly variation in 2026 depending on whether revenue was recognized.

On governance, a dual structure has emerged in which registered majority ownership and de facto control are separated, with related stakes set to shift over the coming years under a call-option arrangement.

Valuation should account for the enlarged equity base and expanded cash liquidity resulting from the capital raise, and it should be noted that price targets issued by multiple brokerages predate the APB-A1 development setback.

Overall, the company has laid the financial groundwork for pipeline expansion, but the market appears to be in a phase awaiting clarity on the indication pivot for its core asset and the materialization of new partnering outcomes.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.